Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors

A combination therapy with pegylated interferon (PEG-IFN) plus ribavirin (RBV) has made it possible to achieve a sustained virological response (SVR) of 50% in refractory cases with genotype 1b and high levels of plasma HCVRNA. Several factors including virus mutation and host factors such as age, g...

Descripción completa

Detalles Bibliográficos
Autores principales: Izumi, Namiki, Asahina, Yasuhiro, Kurosaki, Masayuki
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003995/
https://www.ncbi.nlm.nih.gov/pubmed/21188200
http://dx.doi.org/10.1155/2010/703602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003995/
https://www.ncbi.nlm.nih.gov/pubmed/21188200
http://dx.doi.org/10.1155/2010/703602

Ejemplares similares